ClinicalTrials.gg

Program

rezvilutamide

Also written as “SHR3680”, “Rezvilutamide Tablets” and “SHR3680 tablets”.

Its studies are mostly in Prostatic Neoplasms, led by Jiangsu HengRui Medicine.

Furthest: phase 3, since Apr 27, 201813 company-led studies, 3 open or runningNext primary completion: Mar 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine133 open or runningphase 3since Apr 27, 2018Feb 17, 2016Mar 2027phase 3 · NCT07241416

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 17, 2016First study: phase 2 study in Prostatic NeoplasmsFirst studyNCT02691975 · 197 enrolled · China
  2. Apr 19, 2016Phase 1 study in NeoplasmsNCT02747342 · 33 enrolled · Australia
  3. Apr 27, 2018Phase 3 study in Prostatic NeoplasmsNCT03520478 · 654 enrolled · Bulgaria, China, Czechia and more
  4. Sep 23, 2019Phase 2 study in Prostatic NeoplasmsNCT04102124 · 20 enrolled · China
  5. Oct 22, 2020Phase 2 study in Prostate Cancer MetastaticNCT04603833 · 150 enrolled · China
  6. Nov 3, 20204 phase 1 studiesNCT04621669, NCT04631549, NCT04676035 and 1 more
  7. May 6, 2021Phase 1 study in Healthy Male SubjectsNCT04903158 · 48 enrolled · China
  8. Aug 9, 2021Phase 3 study in Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical ProstatectomyNCT05009290 · 391 enrolled · China
  9. Oct 12, 2022Phase 1 study in Castration-Resistant Prostate CancerNCT05607693 · 52 planned · China
  10. Nov 17, 2025Phase 3 study in Metastatic Hormone-sensitive Prostate Cancer (mHSPC)NCT07241416 · 206 planned · China

Ahead

  1. Mar 2027Primary completion: phase 3 study in Metastatic Hormone-sensitive Prostate Cancer (mHSPC)NCT07241416

TargetBeta

AR →read by rule
“An orally bioavailable androgen receptor (AR) antagonist ”NCIt, by rule
“Androgen Receptor antagonist”ChEMBL 37, by rule

Other programs on AR

ProgramCompanyFurthest phaseStudies
enzalutamideruleAstellas Pharmaphase 469
apalutamideruleJohnson & Johnsonphase 431
darolutamideruleBayerphase 426
Clascoteronerulecassiopea-spaphase 419
ostarinerulegtxphase 315
dezandrodegruleBristol-Myers Squibbphase 35
Cyproterone AcetateruleEurofarma Laboratoriosphase 34
Androgen Receptor-targeting Regulated Induced Proximity Targeting Chimera HLD-0915Johnson & Johnsonphase 33
HRS-5041Jiangsu HengRui Medicinephase 26
luxdegalutamideNovartisphase 23
luxdegalutamideNovartisphase 22
Androgen Receptor Degrader AZD9750ruleAstraZenecaphase 21

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07241416Metastatic Hormone-sensitive Prostate Cancer (mHSPC) · China3RecruitingMar 2027206
NCT05607693Castration-Resistant Prostate Cancer · China1RecruitingNov 5, 202452
NCT05009290Patients With High-risk Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy · China3TerminatedSep 6, 2024391
NCT04903158Healthy Male Subjects · China1UNKNOWNMar 15, 202148
NCT04676035Prostate Cancer Patients · China1CompletedJan 26, 202218
NCT04664725Prostate Cancer Patients · China1UNKNOWNJan 202118
NCT04631549Hepatic Impairment · China1UNKNOWNJul 202324
NCT04621669Drug-drug Interaction,SHR3680 · China1CompletedSep 8, 202136
NCT04603833Prostate Cancer Metastatic · China2UNKNOWNOct 1, 2022150
NCT04102124Prostatic Neoplasms · China2TerminatedAug 31, 202120
NCT03520478Prostatic Neoplasms · Bulgaria, China, Czechia and more3Active, not recruitingApr 30, 2023654
NCT02747342Neoplasms · Australia1CompletedJun 28, 201933
NCT02691975Prostatic Neoplasms · China2UNKNOWNDec 1, 2020197

How it is read

Names in the registry

  • “SHR3680”, 6 entries
  • “Rezvilutamide Tablets”, 1 entry
  • “SHR3680 tablets”, 1 entry
  • “Midazolam, Warfarin, Omeprazole, VitaminK1 and SHR3680”, 1 entry
  • “test SHR3680 tablets”, 1 entry

Codes read as this program: SHR3680.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.